Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Experimental RNAi02:15

Experimental RNAi

8.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K
RNA Interference01:23

RNA Interference

28.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ImageNet3D: Towards General-Purpose Object-Level 3D Understanding.

Advances in neural information processing systems·2026
Same author

Proximity-Driven Protein Ligation Beyond the Concentration Limit.

Journal of the American Chemical Society·2026
Same author

Correction: Coulter et al. OrgTRx: A Platform Developed in Queensland for the Extraction and Visualisation of Antimicrobial Susceptibility Data for the Surveillance of Resistance in Microorganisms. <i>Antibiotics</i> 2026, <i>15</i>, 63.

Antibiotics (Basel, Switzerland)·2026
Same author

Proactive Health: A Culture-Centered Study on the Differential Health Practices of Older Adults in Elderly Care Institutions in China.

Health communication·2026
Same author

Direct Photoredox Synthesis of <i>N</i>-Linked Glycoproteins.

Journal of the American Chemical Society·2026
Same author

The Queensland Bloodstream Infections (QBSI) study: rationale, protocol development and future directions.

Infectious diseases (London, England)·2026

Related Experiment Video

Updated: Feb 19, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.

So C Wong1, Weijun Cheng2, Holly Hamilton2

  • 1Arrowhead Pharmaceuticals Inc., Madison, Wisconsin. swong@arrowheadpharma.com.

Molecular Cancer Therapeutics
|October 29, 2017
PubMed
Summary

A novel RNAi therapeutic targeting hypoxia-inducible factor 2α (HIF2α) shows promise for metastatic clear cell renal cell carcinoma (ccRCC). This approach inhibited tumor growth in a preclinical model, offering a potential new treatment for patients resistant to current therapies.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K

Related Experiment Videos

Last Updated: Feb 19, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Metastatic clear cell renal cell carcinoma (ccRCC) often becomes refractory to standard VEGF and mTOR targeted therapies.
  • Loss of von Hippel-Lindau protein (pVHL) function in ccRCC leads to hypoxia-inducible factor 2α (HIF2α) accumulation, driving tumor growth.
  • There is a critical need for novel therapeutic strategies for advanced ccRCC.

Purpose of the Study:

  • To develop and evaluate a novel RNA interference (RNAi) therapeutic targeting HIF2α for ccRCC.
  • To assess the efficacy of this RNAi therapeutic in inhibiting ccRCC tumor growth in a preclinical setting.

Main Methods:

  • Development of an RNAi therapeutic designed to silence HIF2α.
  • Incorporation of a targeting ligand that binds to integrins αvβ3 and αvβ5, which are overexpressed in ccRCC.
  • Testing the therapeutic's efficacy in an orthotopic ccRCC xenograft mouse model.

Main Results:

  • The RNAi therapeutic successfully achieved HIF2α gene silencing.
  • Functional delivery of the therapeutic led to significant inhibition of tumor growth.
  • Tumor degeneration was observed in the treated ccRCC xenograft model.

Conclusions:

  • A HIF2α-specific RNAi therapeutic demonstrates potential as an innovative treatment for ccRCC.
  • Targeting HIF2α via RNAi offers a promising strategy for overcoming therapeutic resistance in ccRCC.
  • This approach warrants further investigation for clinical application in ccRCC patients.